Richard S Levy Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Richard S Levy.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Richard S Levy. Richard S Levy is EVP, Chief Drug Dev Officer in INCYTE CORP ($INCY) and EVP, Chief Drug Dev&Medical Of in INCYTE CORP ($INCY) and Director in MADRIGAL PHARMACEUTICALS, INC. ($SNTA) and Director in ArTara Therapeutics, Inc. ($PRTO) and Director in CONSTELLATION PHARMACEUTICALS INC ($CNST) and Director in Kodiak Sciences Inc. ($KOD) and Director in Kiniksa Pharmaceuticals, Ltd. ($KNSA).
Latest Insider Trading Transactions of Richard S Levy
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, CNST, INCY, KNSA, KOD, SNTA, TARA
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 02 2020 | KOD | Kodiak Sciences In ... | Levy Richard S | Director | Option Exercise | A | 54.12 | 7,106 | 384,577 | 7,106 | |
Jul 02 2020 | KNSA | Kiniksa Pharmaceut ... | Levy Richard S | Director | Option Exercise | A | 25.48 | 18,760 | 478,005 | 18,760 | |
Jun 18 2020 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Option Exercise | A | 111.06 | 6,000 | 666,360 | 6,000 | |
Jun 11 2020 | TARA | Protara Therapeuti ... | Levy Richard S | Director | Option Exercise | A | 35.00 | 9,000 | 315,000 | 9,000 | |
Jun 10 2020 | KOD | Kodiak Sciences In ... | Levy Richard S | Director | Option Exercise | A | 62.50 | 4,135 | 258,438 | 4,135 | |
Apr 06 2020 | CNST | CONSTELLATION PHAR ... | Levy Richard S | Director | Option Exercise | A | 30.29 | 26,342 | 797,899 | 26,342 | |
Mar 24 2020 | KOD | Kodiak Sciences In ... | Levy Richard S | Director | Buy | P | 44.65 | 750 | 33,488 | 1,000 | 250 to 1,000 (+300.00 %) |
Mar 24 2020 | KOD | Kodiak Sciences In ... | Levy Richard S | Director | Buy | P | 43.37 | 250 | 10,843 | 250 | 0 to 250 |
Jan 13 2020 | PRTO | ArTara Therapeutic ... | Levy Richard S | Director | Grant | A | 0.00 | 31,000 | 0 | 31,000 | 0 to 31 K |
Jul 01 2019 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Option Exercise | A | 100.45 | 10,000 | 1,004,500 | 10,000 | |
Jun 05 2019 | KOD | Kodiak Sciences In ... | Levy Richard S | Director | Option Exercise | A | 10.13 | 24,747 | 250,687 | 24,747 | |
Mar 06 2019 | KNSA | Kiniksa Pharmaceut ... | Levy Richard S | Director | Option Exercise | A | 17.92 | 37,965 | 680,333 | 37,965 | |
Jun 21 2018 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Option Exercise | A | 303.79 | 10,000 | 3,037,900 | 10,000 | |
Aug 24 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.25 | 7 | 114 | 9,100 | 9.1 K to 9.1 K (+0.08 %) |
Aug 24 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.12 | 1,793 | 28,903 | 9,093 | 7.3 K to 9.1 K (+24.56 %) |
Aug 24 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.11 | 100 | 1,611 | 7,300 | 7.2 K to 7.3 K (+1.39 %) |
Aug 24 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.08 | 100 | 1,608 | 7,200 | 7.1 K to 7.2 K (+1.41 %) |
Aug 23 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.14 | 127 | 2,050 | 7,100 | 7 K to 7.1 K (+1.82 %) |
Aug 23 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.12 | 2,944 | 47,457 | 6,973 | 4 K to 7 K (+73.07 %) |
Aug 23 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.10 | 389 | 6,263 | 4,029 | 3.6 K to 4 K (+10.69 %) |
Aug 23 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.99 | 90 | 1,439 | 3,640 | 3.6 K to 3.6 K (+2.54 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.09 | 590 | 9,493 | 3,550 | 3 K to 3.6 K (+19.93 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.07 | 440 | 7,071 | 2,960 | 2.5 K to 3 K (+17.46 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.04 | 210 | 3,368 | 2,520 | 2.3 K to 2.5 K (+9.09 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.02 | 200 | 3,204 | 2,310 | 2.1 K to 2.3 K (+9.48 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.93 | 200 | 3,186 | 2,110 | 1.9 K to 2.1 K (+10.47 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.90 | 10 | 159 | 1,910 | 1.9 K to 1.9 K (+0.53 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.80 | 400 | 6,320 | 1,900 | 1.5 K to 1.9 K (+26.67 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.79 | 200 | 3,158 | 1,500 | 1.3 K to 1.5 K (+15.38 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.77 | 200 | 3,154 | 1,300 | 1.1 K to 1.3 K (+18.18 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.72 | 100 | 1,572 | 1,100 | 1,000 to 1.1 K (+10.00 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.70 | 100 | 1,570 | 1,000 | 900 to 1,000 (+11.11 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.67 | 900 | 14,103 | 900 | 0 to 900 |
Jun 30 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Option Exercise | A | 16.46 | 10,000 | 164,600 | 10,000 | |
Nov 21 2016 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Option Exercise | A | 7.36 | 20,000 | 147,200 | 20,000 | |
Jan 08 2016 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 3,937 | 72,126 | 2,876 | |
Jan 08 2016 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 101.86 | 3,937 | 401,023 | 16,926 | 20.9 K to 16.9 K (-18.87 %) |
Jan 08 2016 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 3,937 | 72,126 | 20,863 | 16.9 K to 20.9 K (+23.26 %) |
Dec 09 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 3,937 | 72,126 | 6,813 | |
Dec 09 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 106.18 | 3,937 | 418,031 | 16,926 | 20.9 K to 16.9 K (-18.87 %) |
Dec 09 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 3,937 | 72,126 | 20,863 | 16.9 K to 20.9 K (+23.26 %) |
Nov 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 3,936 | 72,108 | 10,750 | |
Nov 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 116.51 | 3,936 | 458,583 | 16,926 | 20.9 K to 16.9 K (-18.87 %) |
Nov 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 3,936 | 72,108 | 20,862 | 16.9 K to 20.9 K (+23.25 %) |
Oct 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 3,937 | 72,126 | 14,686 | |
Oct 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 122.29 | 3,937 | 481,456 | 16,926 | 20.9 K to 16.9 K (-18.87 %) |
Oct 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 3,937 | 72,126 | 20,863 | 16.9 K to 20.9 K (+23.26 %) |
Sep 15 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 130.00 | 4,301 | 559,130 | 16,926 | 21.2 K to 16.9 K (-20.26 %) |
Sep 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 3,937 | 72,126 | 18,623 | |
Sep 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 118.90 | 3,937 | 468,109 | 21,227 | 25.2 K to 21.2 K (-15.65 %) |
Sep 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 3,937 | 72,126 | 25,164 | 21.2 K to 25.2 K (+18.55 %) |
Aug 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 3,936 | 72,108 | 22,560 | |
Aug 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 111.95 | 3,936 | 440,635 | 21,227 | 25.2 K to 21.2 K (-15.64 %) |
Aug 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 3,936 | 72,108 | 25,163 | 21.2 K to 25.2 K (+18.54 %) |
Jul 16 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 17.79 | 70,217 | 1,249,160 | 0 | |
Jul 16 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 120.00 | 70,217 | 8,426,040 | 21,227 | 91.4 K to 21.2 K (-76.79 %) |
Jul 16 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 17.79 | 70,217 | 1,249,160 | 91,444 | 21.2 K to 91.4 K (+330.79 %) |
Jul 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 3,937 | 72,126 | 26,496 | |
Jul 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 107.00 | 3,937 | 421,259 | 21,227 | 25.2 K to 21.2 K (-15.65 %) |
Jul 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 3,937 | 72,126 | 25,164 | 21.2 K to 25.2 K (+18.55 %) |
Jun 23 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 17.79 | 20,000 | 355,800 | 70,217 | |
Jun 23 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 108.13 | 20,000 | 2,162,600 | 21,227 | 41.2 K to 21.2 K (-48.51 %) |
Jun 23 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 17.79 | 20,000 | 355,800 | 41,227 | 21.2 K to 41.2 K (+94.22 %) |
Jun 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 3,937 | 72,126 | 30,433 | |
Jun 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 107.58 | 3,937 | 423,542 | 21,227 | 25.2 K to 21.2 K (-15.65 %) |
Jun 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 3,937 | 72,126 | 25,164 | 21.2 K to 25.2 K (+18.55 %) |
May 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 7,412 | 135,788 | 34,370 | |
May 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 99.43 | 7,412 | 736,975 | 21,227 | 28.6 K to 21.2 K (-25.88 %) |
May 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 7,412 | 135,788 | 28,639 | 21.2 K to 28.6 K (+34.92 %) |
Apr 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 25,000 | 458,000 | 41,782 | |
Apr 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 88.77 | 25,000 | 2,219,250 | 21,227 | 46.2 K to 21.2 K (-54.08 %) |
Apr 08 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 25,000 | 458,000 | 46,227 | 21.2 K to 46.2 K (+117.77 %) |
Mar 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 18.32 | 25,000 | 458,000 | 66,782 | |
Mar 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 89.91 | 25,000 | 2,247,750 | 21,227 | 46.2 K to 21.2 K (-54.08 %) |
Mar 10 2015 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 18.32 | 25,000 | 458,000 | 46,227 | 21.2 K to 46.2 K (+117.77 %) |
Oct 24 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 3.11 | 13,904 | 43,241 | 0 | |
Oct 24 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 3.11 | 13,904 | 43,241 | 18,205 | 4.3 K to 18.2 K (+323.27 %) |
Oct 20 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 14.72 | 8,000 | 117,760 | 44,317 | |
Oct 20 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 49.03 | 8,000 | 392,240 | 4,301 | 12.3 K to 4.3 K (-65.04 %) |
Oct 20 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 14.72 | 8,000 | 117,760 | 12,301 | 4.3 K to 12.3 K (+186.00 %) |
Sep 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 14.72 | 8,000 | 117,760 | 52,317 | |
Sep 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 47.58 | 8,000 | 380,640 | 4,301 | 12.3 K to 4.3 K (-65.04 %) |
Sep 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 14.72 | 8,000 | 117,760 | 12,301 | 4.3 K to 12.3 K (+186.00 %) |
Aug 19 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 14.72 | 8,000 | 117,760 | 60,317 | |
Aug 19 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 51.97 | 8,000 | 415,760 | 4,301 | 12.3 K to 4.3 K (-65.04 %) |
Aug 19 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 14.72 | 8,000 | 117,760 | 12,301 | 4.3 K to 12.3 K (+186.00 %) |
Jul 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 14.72 | 8,000 | 117,760 | 68,317 | |
Jul 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 48.15 | 8,000 | 385,200 | 4,301 | 12.3 K to 4.3 K (-65.04 %) |
Jul 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 14.72 | 8,000 | 117,760 | 12,301 | 4.3 K to 12.3 K (+186.00 %) |
Jun 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 14.72 | 8,000 | 117,760 | 76,317 | |
Jun 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 53.88 | 8,000 | 431,040 | 4,301 | 12.3 K to 4.3 K (-65.04 %) |
Jun 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 14.72 | 8,000 | 117,760 | 12,301 | 4.3 K to 12.3 K (+186.00 %) |
May 20 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 14.72 | 8,000 | 117,760 | 84,317 | |
May 20 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 50.68 | 8,000 | 405,440 | 4,301 | 12.3 K to 4.3 K (-65.04 %) |
May 20 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 14.72 | 8,000 | 117,760 | 12,301 | 4.3 K to 12.3 K (+186.00 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 13.34 | 417 | 5,563 | 0 | |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 13.34 | 14,583 | 194,537 | 0 | |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 9.41 | 24,787 | 233,246 | 0 | |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 11.98 | 1,945 | 23,301 | 0 | |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 11.98 | 9,138 | 109,473 | 0 | |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 9.41 | 12,300 | 115,743 | 0 | |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 11.98 | 25,862 | 309,827 | 0 | |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 9.41 | 47,913 | 450,861 | 24,787 | |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 3.11 | 61,096 | 190,009 | 0 | |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 11.98 | 33,055 | 395,999 | 0 | |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 66.13 | 39,787 | 2,631,114 | 4,301 | 44.1 K to 4.3 K (-90.24 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 13.34 | 417 | 5,563 | 44,088 | 43.7 K to 44.1 K (+0.95 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 13.34 | 14,583 | 194,537 | 43,671 | 29.1 K to 43.7 K (+50.13 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 9.41 | 24,787 | 233,246 | 29,088 | 4.3 K to 29.1 K (+576.31 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 66.38 | 191,309 | 12,699,091 | 4,301 | 195.6 K to 4.3 K (-97.80 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 11.98 | 1,945 | 23,301 | 195,610 | 193.7 K to 195.6 K (+1.00 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 11.98 | 9,138 | 109,473 | 193,665 | 184.5 K to 193.7 K (+4.95 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 9.41 | 12,300 | 115,743 | 184,527 | 172.2 K to 184.5 K (+7.14 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 11.98 | 25,862 | 309,827 | 172,227 | 146.4 K to 172.2 K (+17.67 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 9.41 | 47,913 | 450,861 | 146,365 | 98.5 K to 146.4 K (+48.67 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 3.11 | 61,096 | 190,009 | 98,452 | 37.4 K to 98.5 K (+163.55 %) |
Feb 18 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 11.98 | 33,055 | 395,999 | 37,356 | 4.3 K to 37.4 K (+768.54 %) |
Jan 23 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | A | 64.55 | 34,868 | 2,250,729 | 34,868 | |
Jan 23 2014 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | A | 64.55 | 997 | 64,356 | 997 | |
Sep 09 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 11.98 | 25,000 | 299,500 | 862 | |
Sep 09 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 35.28 | 25,000 | 882,000 | 0 | 25 K to 0 (-100.00 %) |
Sep 09 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 11.98 | 25,000 | 299,500 | 25,000 | 0 to 25 K |
May 15 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 7.09 | 4,301 | 30,494 | 0 | |
May 15 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 7.09 | 55,699 | 394,906 | 0 | |
May 15 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 22.30 | 55,699 | 1,242,088 | 4,301 | 60 K to 4.3 K (-92.83 %) |
May 15 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 7.09 | 4,301 | 30,494 | 60,000 | 55.7 K to 60 K (+7.72 %) |
May 15 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 7.09 | 55,699 | 394,906 | 55,699 | 0 to 55.7 K |
Feb 20 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 8.99 | 38,440 | 345,576 | 0 | |
Feb 20 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 5.46 | 16,251 | 88,730 | 0 | |
Feb 20 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 5.46 | 43,749 | 238,870 | 0 | |
Feb 20 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 22.48 | 98,440 | 2,212,931 | 0 | 98.4 K to 0 (-100.00 %) |
Feb 20 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 8.99 | 38,440 | 345,576 | 98,440 | 60 K to 98.4 K (+64.07 %) |
Feb 20 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 5.46 | 16,251 | 88,730 | 60,000 | 43.7 K to 60 K (+37.15 %) |
Feb 20 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 5.46 | 43,749 | 238,870 | 43,749 | 0 to 43.7 K |
Feb 12 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | A | 18.32 | 141,782 | 2,597,446 | 141,782 | |
Feb 12 2013 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | A | 18.32 | 8,218 | 150,554 | 8,218 | |
May 01 2012 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 8.19 | 8,440 | 69,124 | 0 | |
May 01 2012 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 8.99 | 9,751 | 87,661 | 38,440 | |
May 01 2012 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 8.99 | 11,809 | 106,163 | 0 | |
May 01 2012 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 22.95 | 30,000 | 688,500 | 0 | 30 K to 0 (-100.00 %) |
May 01 2012 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 8.19 | 8,440 | 69,124 | 30,000 | 21.6 K to 30 K (+39.15 %) |
May 01 2012 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 8.99 | 9,751 | 87,661 | 21,560 | 11.8 K to 21.6 K (+82.57 %) |
May 01 2012 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Buy | M | 8.99 | 11,809 | 106,163 | 11,809 | 0 to 11.8 K |
Jan 23 2012 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | A | 17.79 | 93,900 | 1,670,481 | 93,900 | |
Jan 23 2012 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | A | 17.79 | 6,100 | 108,519 | 6,100 | |
Jan 27 2011 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | A | 14.72 | 92,317 | 1,358,906 | 92,317 | |
Jan 27 2011 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | A | 14.72 | 7,683 | 113,094 | 7,683 | |
Jan 20 2011 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 8.19 | 25,310 | 207,289 | 0 | |
Jan 20 2011 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Option Exercise | M | 4.19 | 15,000 | 62,850 | 0 | |
Jan 20 2011 | INCY | INCYTE CORP | Levy Richard S | EVP, Chief Drug Dev ... | Sell | S | 15.77 | 6,400 | 100,928 | 0 | 6.4 K to 0 (-100.00 %) |